Compare Infosys Limited (INFY) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Stryker Corporation — how do they compare? Infosys Limited trades at $10.74 (market cap $41.74B), while Stryker Corporation trades at $277.34 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 2.5× Infosys Limited's market cap, and Infosys Limited pays the higher dividend (4.89%). Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Stryker Corporation for 21 Days on average.
| INFY | SYK | |
|---|---|---|
Market Cap | $41.74B | $106.24B |
Volume | 31,354,285 | 2,982,001 |
Sector | Technology | Health |
52-Week High | $20.22 | $388.35 |
52-Week Low | $10.49 | $269.75 |
Typical Hold Time | 27 Days | 21 Days |
Enterprise Value | $39.48B | $117.70B |
Dividend Yield | 4.89% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.75, up 1.9% in the last 24 hours, with a bearish technical signal from moving averages. The company reported a net income of $3.16B on $19.28B revenue for 2025, with profitability metrics like a 16.37% net margin and 32.12% ROE. Recent news highlights strategic AI collaborations, such as with Columbia University and ABN Amro, to drive innovation. Earnings have been mixed, with beats in Q4 2025 and Q1 2026 but a miss in Q2 2026.
The outlook is cautious; while valuation ratios like a P/E of 13.21 appear reasonable and analyst consensus targets $11.48, weak IT spending and AI pricing pressure pose risks. Institutional sentiment is mixed with 35% buy ratings, but negative cash flow trends in 2026 forecast demand careful monitoring of execution against guidance.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
